Glaukos Corporation Announces Fourth Quarter and Full Year 2018 Financial Results

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, today announced financial results for the fourth quarter and full year ended December 31, 2018. Key highlights include: Achieved 30% net sales growth to $54.1 million in the fourth quarter of 2018, compa

Full Story →